Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8803 USD | -5.36% | -6.45% | +8.68% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.68% | 87.11M | |
+31.52% | 690B | |
+24.55% | 546B | |
-5.21% | 358B | |
+17.02% | 323B | |
+5.01% | 287B | |
+13.94% | 235B | |
+5.13% | 199B | |
-9.94% | 195B | |
+3.98% | 161B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Transcript : HOOKIPA Pharma Inc. - Special Call